The WHO Standard: Universal Access to Rapid Tuberculosis Diagnostics
This WHO publication sets benchmarks to achieve universal access to WHO-recommended rapid diagnostics (WRDs), increase bacteriologically confirmed tuberculosis and drug resistance
Policy Brief and Infographics on Antimicrobial Resistance (AMR) in Africa
This policy brief summarises the results of the Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project, and the analysis and interpretation of antimicrob
WHO Guidance to Support HIV Care Models During the COVID-19 Era
In September 2021 the World Health Organization released updated guidance on maintaining essential health services during COVID-19, which provides direction on modifications and sp
LabCoP Cookbook Recipe #6: How to Maintain HIV and Tuberculosis Testing Services During Health Emergencies
Essential diagnostic tests satisfy priority healthcare needs of a population and are selected based on disease prevalence, public health relevance, evidence of utility and comparat
Diagnostic Pricing Database
Low- and middle-income countries (LMIC) currently experience low testing coverage in the face of increasing demand to meet the needs of millions of people living with HIV, TB, HPV,
LabCoP Cookbook Recipe 5: Quality Management System Considerations and Guidance for COVID-19 Molecular Testing Laboratories
Laboratory diagnosis is an essential element of communicable disease surveillance, both for routine confirmation of infections and for the rapid identification of the cause of outb
Assessment of N95 Respirator Decontamination and Re-use for SARS-CoV-2
In this study, Robert Fischer, et al, present their assessment findings on N95 respirator decontamination and re-use for SARS-CoV-2 (24 April 2020), using four different decontamin
Dolutegravir vs. Efavirenz in Women Starting HIV Therapy in Late Pregnancy (DolPHIN-2)
In this paper, Kenneth Kintu, et al, investigated the virological suppression (achieving viral loads < 50 copies per mL) before giving birth with dolutegravir compared to efavir
Management of Severe COVID-19
David Berlin, et al, present key clinical features of severe COVID-19 in the New England Journal of Medicine (21 May 2020). The authors start with a clinical description of a 50-ye
A Human Monoclonal Antibody Blocking SARS-CoV-2 Infection
In Nature Communications, Chuyan Wang, et al (4 May, 2020) describe a human monoclonal antibody that neutralizes SARS-CoV-2 in cell culture. The authors highlight that the cross-ne